Back to News
Idorsia joins IQ Consortium
August 8, 2022
The IQ Consortium is very pleased to announce its newest member, Idorsia. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.
Idorsia will be represented on the IQ Board of Directors by Olivier Lambert and Markus von Raumer.